INVO BioScience, Inc.

Good day and welcome to the INVO Bioscience first quarter 2022 financial results conference call. Today, all participants will be in a listen only mode. Should you need any assistance, please signal for a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star, then two. Please note that today's event is being recorded. I would now like to turn the conference over to Robert Bloom with Lissom Partners. Please go ahead, sir.

All right. Thank you very much, Chris. Good afternoon, everyone, and thank you all for joining us for today's InvoBioscience first quarter 2022 financial results conference call. Joining us on today's call is InvoBioscience's CEO, Steve Schumm. the company's Chief Operating Officer and VP of Business Development, Mike Campbell, and Andrea Gorin, the company's Chief Financial Officer. At the conclusion of today's prepared remarks, we'll open the call for a question and answer session. Before we begin with the event, we submit for the record the following statement. Certain matters discussed on this conference call by the management of InvoBioscience may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended, Section 21E of the Securities Exchange Act of 1934 is amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements regarding the company's expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans, and objectives of management are for future operations, as well as statements that include words such as anticipate, if, believe, plan, estimate, expect, intend, may, could, should, will, and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond the company's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in the company's filings at www.sec.gov. The companies under no obligation to, and expressly discriminating such obligation to, update or alter our forward-looking statements, whether the result of the new information, future events, or otherwise. So with that said, let me turn the event over to Steve Shum, Chief Executive Officer for INVO Bioscience. Steve, please proceed.

Thank you, Robert, and welcome, everyone. We will plan to keep our prepared remarks shorter today since we covered a fair amount of detail on our recent year-end results call, which just took place six weeks ago, and as a reminder, included a new slide presentation covering key details of our INVO Center strategy. So for today, we will focus on important progress and data since that year-end conference call. Overall, the business is moving well on all of our key fronts. We continue to see growth trends building at the existing INBO centers. Our multi-channel marketing programs, which we started in Atlanta, are really starting to make a difference and impact Atlanta. We are now applying similar efforts in both Birmingham and Mexico. Those key metrics, inbound patient inquiries, consultations, and patients working through initial testing to confirm if they are suitable for fertility treatment, which are all important precursors to larger revenue resulting from actual IVC cycles, are all trending very well, and that flow is running at a stepped-up level just in the past few weeks. Michael touched on a few specific metrics in a moment. We are also learning and gaining valuable insight with these marketing programs regarding what is having the best patient conversion rates. As we stated previously, we will look to deploy these tactics in a more concerted manner to accelerate the cycle ramp in future clinics. We announced our intent to open new centers, which is consistent with our previously stated goals to expand our InvoCenter footprint. We are in the early phases of all the necessary steps to open these centers, in a timely manner per our plan expectations. Our Tampa lease is in final review. I'm pleased to report that we will reduce part of the upfront investment required to bring new centers operational through the use of equipment leasing and higher TI build-out allocation being incorporated into the lease rate for the space. Ongoing discussions with potential clinician partners are also progressing well. we are finding strong interest in sharing our mission to deliver affordable care to underserved patients. Again, as this strategy continues to evolve, we may also find ways to further expand or evolve our efforts, which could lower costs and accelerate timing. We hope to report more on this in the near future. This could be a favorable improvement for the cost structure and capital requirements associated with our expansion. We are also seeing encouraging activity with our US distribution activities. Since early February, when we took over from Faring and began direct sales efforts with the existing IVF clinics, we have seen growing order flow each month, but equally important, we are finding strong interest in the InvoCell technology and desire for expanding utilization within the clinics. These direct efforts have yielded a number of clinics to commit to much higher usage throughout the balance of 2022. We also saw orders in the first quarter from certain international distributors. And on Friday of just last week, we signed a new meaningful distribution agreement for China. Because that occurred on Friday, we mentioned it on the earnings release and as a subsequent event in the 10Q, but we also just issued a standalone release on it to provide some additional color to make sure all the information was available together. We've been pursuing China for probably going on two plus years now. This distributor was the result of seven or eight months of active discussion and negotiation with this China partner. We certainly wanted to take our time regarding this important market as finding the right partner is critical, and it just happened to conclude right on top of our Q1 release. With respect to our five-day clinical label efforts, we are just finalizing the submission and expect to submit that at the end of this month. With that, I will turn this over to Mike for additional comments on our commercialization efforts. Mike?